TCM
EBS icon

Tributary Capital Management’s Emergent Biosolutions EBS Stock Holding History

Tributary Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-126,809
Closed -$6.41M – 210
2019
Q1 		$6.41M Buy
126,809
+14,223
+13% +$839K 0.46% 63
2018
Q4 		$6.67M Buy
112,586
+1,372
+1% +$88.4K 0.61% 63
2018
Q3 		$7.32M Buy
111,214
+14,247
+15% +$831K 0.56% 63
2018
Q2 		$4.9M Buy
+96,967
New +$5.05M 0.38% 65

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Tributary Capital Management's EBS Position: Q2 2019 in Review

Tributary Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2019, closing a stake of 126,809 shares — an estimated $6.41M sold.

Tributary Capital Management first reported a position in EBS in Q2 2018 and held it in 4 quarters. The position peaked at $7.32M in Q3 2018. 233 funds tracked by Wall St. Rank hold EBS as of Q2 2019.

  • Tributary Capital Management reported no remaining Emergent Biosolutions position as of Q2 2019 after selling out during the quarter.
  • Tributary Capital Management sold 126,809 Emergent Biosolutions shares in Q2 2019, an estimated $6.41M.
  • Tributary Capital Management first reported a position in Emergent Biosolutions in Q2 2018 and held it in 4 quarters.
  • Tributary Capital Management's Emergent Biosolutions position peaked at $7.32M in Q3 2018.
  • 233 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2019.

Based on Tributary Capital Management's 13F filing for Q2 2019, filed 11 Jul 2019.